<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(3)</volume><submitter>Barski D</submitter><pubmed_abstract>The gene for the tissue inhibitor of metalloproteinase 3 (TIMP3) on 22q12.3 had been reported to be inactivated by promoter methylation in various types of cancers, with controversial findings in meningiomas. We performed direct sodium bisulfite sequencing in a series of 50 meningiomas, including 27 benign meningiomas [World Health Organization (WHO) grade I], 11 atypical meningiomas (WHO grade II) and 12 anaplastic meningiomas (WHO grade III), and found hypermethylation of TIMP3 in 67% of anaplastic meningiomas, but only 22% of atypical and 17% of benign meningiomas. Moreover, TIMP3 methylation scores were significantly inversely correlated with TIMP3 mRNA expression levels (P = 0.0123), and treatment of the meningioma cell line Ben-Men-1 with demethylating agents induced an increased TIM</pubmed_abstract><journal>Brain pathology (Zurich, Switzerland)</journal><pagination>623-31</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8094659</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas.</pubmed_title><pmcid>PMC8094659</pmcid><pubmed_authors>Reifenberger G</pubmed_authors><pubmed_authors>Barski D</pubmed_authors><pubmed_authors>Riemenschneider MJ</pubmed_authors><pubmed_authors>Wolter M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas.</name><description>The gene for the tissue inhibitor of metalloproteinase 3 (TIMP3) on 22q12.3 had been reported to be inactivated by promoter methylation in various types of cancers, with controversial findings in meningiomas. We performed direct sodium bisulfite sequencing in a series of 50 meningiomas, including 27 benign meningiomas [World Health Organization (WHO) grade I], 11 atypical meningiomas (WHO grade II) and 12 anaplastic meningiomas (WHO grade III), and found hypermethylation of TIMP3 in 67% of anaplastic meningiomas, but only 22% of atypical and 17% of benign meningiomas. Moreover, TIMP3 methylation scores were significantly inversely correlated with TIMP3 mRNA expression levels (P = 0.0123), and treatment of the meningioma cell line Ben-Men-1 with demethylating agents induced an increased TIM</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 May</publication><modification>2026-05-09T11:40:25.109Z</modification><creation>2022-02-11T10:11:21.058Z</creation></dates><accession>S-EPMC8094659</accession><cross_references><pubmed>19922547</pubmed><doi>10.1111/j.1750-3639.2009.00340.x</doi></cross_references></HashMap>